Newly reported results of a small phase 2 clinical trial indicate the potential utility of using nitrous oxide treatments in patients with severe major depression that has not responded to other…
Read More
Imagine a new treatment for people with major depression who have not responded to existing treatments—one that acts rapidly and helps a much larger fraction of such patients than any current…
Read More
Carefully designed, exquisitely controlled experiments sometimes don't produce the result predicted in advance—the research “hypothesis” that is the starting point for a program of research. That is…
Read More
In the spring of 2019, The Food and Drug Administration granted approval for two breakthrough medicines that act rapidly to alleviate symptoms of major depression. Esketamine, a drug administered via…
Read More
Researchers led by 2013 BBRF Young Investigator Conor Liston, M.D., Ph.D., have just reported a surprising finding about the drug ketamine, concerning the way it acts on the brain.
Approved many…
Read More
